The Clostridia Technology Company

CHAIN Biotechnology Ltd was founded by Dr Edward Green in 2014 to develop new Clostridium-based microbial technology for high value healthcare products. CHAIN produces novel 2nd generation live biotherapeutic products (LBPs) for chronic gut-related diseases, such as Inflammatory Bowel Disease (IBD).

Anaerobic Clostridia bacteria, naturally present in healthy human guts, produce short-chain fatty acids and antimicrobial peptides which aid the immune system as part of a healthy gut microbiome. Disturbance of the gut microbiome (dysbiosis) may result in damage to both mucosal and epithelial cell membranes resulting in chronic diseases like IBD, but also colon cancer, diabetes, obesity, and auto-immune disorders.

CHAIN’s unique therapeutic platform is enabled by world leading scientific expertise and a suite of advanced synthetic biology tools to deliver therapeutic payloads via a patented in-vivo delivery mechanism based on Clostridium.

CHAIN is based at Jubilee House, Marlow and the core technical team is embedded within the Synthetic Biology Research Centre at the University of Nottingham. CHAIN collaborates with clinicians and medical researchers from Imperial College London and the Universities of Nottingham, Leeds and Cardiff.

CHAIN is on LinkedIn, Twitter, and we can be contacted here.

Management Team